Vivos Therapeutics, Inc. (VVOS)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Vivos Therapeutics, Inc. (VVOS) Q1 2026 Earnings Call Transcript
Vivos Therapeutics, Inc. (VVOS) Q1 2026 Earnings Call Transcript
Vivos Therapeutics, Inc. (VVOS) Q4 2025 Earnings Call Transcript
Vivos Therapeutics, Inc. (VVOS) Q4 2025 Earnings Call Transcript
Vivos Therapeutics (VVOS) Upgraded to Buy: Here's What You Should Know
Vivos Therapeutics (VVOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Vivos Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Anthony Scaramucci SkyBridge Capital II LLC | 1.12M | $1.32M | $458,283.29 | -$858,430.66 | -65.19% |
| YA Yinka Akinsola Blue Trust Inc. | 160 | $772.8 | $66.78 | -$706.02 | -91.36% |
 Jill Grimes Centurion Wealth Management LLC | 35,684 | $42,108 | $14,685.75 | -$27,422.25 | -65.12% |
Vivos Therapeutics, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| LW Lucas Ward Ascendiant Capital | 12.68B | $23.08B | $5.23B | -$17.85B | -77.32% |
Vivos Therapeutics, Inc. (VVOS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Vivos Therapeutics, Inc. ever had a stock split?
Vivos Therapeutics, Inc. Profile
| Automobiles Industry | Consumer Discretionary Sector | R. Kirk Huntsman CEO | NASDAQ (CM) Exchange | 92859E207 CUSIP |
| US Country | 268 Employees | - Last Dividend | 27 Oct 2023 Last Split | 11 Dec 2020 IPO Date |
Overview
Vivos Therapeutics, Inc., established in 2016 and based in Highlands Ranch, Colorado, operates as a medical technology company focused on innovating and commercializing treatment options for patients suffering from dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring. The company's approach emphasizes non-invasive, non-surgical, and non-pharmaceutical treatment modalities, aiming to provide revolutionary care for adults exhibiting these conditions. Vivos Therapeutics engages primarily with licensed professionals, especially general dentists in the United States and Canada, to market and sell its proprietary solutions, ensuring a broad reach and impact on affected patient communities.
Products and Services
- Vivos System
This flagship offering by Vivos Therapeutics represents a comprehensive, multi-disciplinary treatment modality designed to address dentofacial abnormalities, OSA, and snoring in adults. Distinguished by its non-invasive, non-surgical, and non-pharmaceutical approach, the Vivos System leverages the body's natural healing processes to realize significant, lasting health improvements. It stands as a hallmark of innovation in the field, emphasizing patient comfort and ease of use while fostering effective outcomes.
- VivoScore Program
Aiming to streamline the initial diagnosis and monitoring process, the VivoScore Program provides an accessible screening and home sleep test that can be utilized by both adults and children. This service facilitates early detection and intervention for sleep-related disorders, underscoring Vivos Therapeutics' commitment to comprehensive patient care from diagnosis through treatment. The convenience and ease of implementation of the VivoScore Program make it an essential component of the company's broader effort to combat OSA and related conditions.
